Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone

Table 3 Subgroup analyses on 6-mo survival rate

Subgroups	Trials	Patients	Mode	RD [95% CI]	P
GEM plus targeted drug vs GEM alone	[13, 14, 26]	1496	Fixed	0.06 [0.01, 0.11]	0.02
GEM plus DDP vs GEM alone	[9, 10, 18, 20, 23, 24]	560	Fixed	0.05 [-0.03, 0.13]	0.24
GEM plus 5-FU vs GEM alone	[12, 22, 28]	881	Random	0.04 [-0.09, 0.17]	0.57
GEM plus topoisomerase I inhibitor vs GEM alone	[16, 21, 24, 27]	928	Fixed	0.01 [-0.05, 0.08]	0.72
GEM plus capecitabine vs GEM alone	[8, 29]	399	Fixed	0.00 [-0.08, 0.10]	0.97